Mostrar Notícias:

SGPPrincipaisÚltima HoraBovespa - Brasil

 Ver notícias de outros activos

Pesquisa de notícias relativas à acção SCHERING PLOUGH C (ordenadas pela data):

Array BioPharma Names Carrie S. Cox Chairman of its Board of ... Markets Insider Before joining Schering-Plough, Ms. Cox served as Executive Vice President and President of Pharmacia's Global Prescription Business, Senior Vice President of Pharmacia & Upjohn's Global Prescription Business, and as Vice President of Women's ... e mais »

Reuters

Keytruda sales power Merck to quarterly beat Reuters (Reuters) - Drugmaker Merck & Co (MRK.N) reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda.

The Economist

A pharmaceutical firm bets big on a cancer drug The Economist Merck's merger with another pharma firm, Schering-Plough, in 2009, had brought it an obscure new cancer drug. At first Merck's scientists were unimpressed and relegated the drug to a list of assets to be licensed out. There was widespread scepticism at ...

The Pharmaceutical Journal

Hepatitis C: tackling the silent killer The Pharmaceutical Journal 1997: The first alpha interferon, Schering-Plough's Intron A (interferon alpha-2B), is approved for treatment of hepatitis C in the UK. 1999: European blood services begin screening blood with nucleic acid amplification testing (NAT), because it ...

Merck, Schering-Plough set to complete merger Reuters NEW YORK (Reuters) - Merck & Co (MRK.N) and Schering-Plough Corp SGP.N said their $41.1 billion merger will be completed later on Tuesday, marking the close of the second huge deal in the pharmaceutical industry in recent weeks. Pfizer Inc (PFE.

Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President ... GlobeNewswire (press release) In this position, she served as clinical lead for the hepatitis B and C and HIV portfolios. She previously worked at Schering-Plough Research Institute as a Director in Hepatology. Prior to working in industry, she was an Epidemic Intelligence Service ...

Business Wire (press release)

Science Exchange Adds Allergan EVP & Chief R&D Officer David ... Business Wire (press release) PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, Inc. announced today that C. David Nicholson, Ph.D., EVP and Chief R&D Officer at Allergan, has joined the Science Exchange Board of Directors. Dr. Nicholson's experience includes over forty ... e mais »

Forbes

What You Should Know About Ken Frazier, The CEO Who Just Quit ... Forbes Kenneth C. Frazier, the chairman and chief executive of the U.S. drug maker Merck, resigned from President Donald Trump's American Manufacturing Council on Monday morning, saying in a statement, ?As CEO of Merck and as a matter of personal conscience ... e mais »

Hannoversche Allgemeine

USA: Deutsche Firma soll Gift für Hinrichtungen geliefert haben Hannoversche Allgemeine Daten des US-Zolls zufolge lieferte VET Pharma die Medikamente an ein US-Schwesterunternehmen, die Intervet Schering-Plough Animal Health. Beide Firmen gehören zum US-Pharmariesen Merck Sharp & Dohme (MSD). Weitere Lieferungen sollen nach ... e mais »

In Vivo

Bristol/Medarex: A Transformational Acquisition Rooted In ... In Vivo Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in ...

GlobeNewswire (press release)

Esperion Announces the Appointment of Jeffrey Berkowitz to Board ... GlobeNewswire (press release) We are confident Jeff will provide important contributions to help us deliver on the promise of bringing our complementary, oral LDL-C lowering therapies to the millions of patients who are inadequately treated with, or unable to gain access to ... e mais »

RTE.ie

Animal medicines company purchases Rathdrum site RTE.ie The world's largest manufacturer of animal medicines and vaccines has bought the former MSD pharmaceutical plant in Rathdrum, Co Wicklow. US-based company Zoetis, which already operates two sites in Ireland, confirmed to RTÉ News this evening it has ... e mais »

TCTMD

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients TCTMD In PROVE-IT, for example, high-intensity statin therapy started within 7 days of ACS showed a clinical benefit, as did early treatment with ezetimibe (Zetia; Merck/Schering-Plough) in IMPROVE-IT. ?But that still leaves the early window,? she added ... e mais »

Lexology

How Spreading Fake News about Your Competitors' Products Will ... Lexology On January 23, 2018, the European Court of Justice (CoJ) handed down an important judgment in the Hoffman-La Roche / Novartis case (C-179/16). For the first time, the CoJ takes a stance on .... Sanofi-Aventis, Schering-Plough and recently Janssen-Cilag ...

Merck, Schering-Plough to complete merger Tuesday MarketWatch BOSTON (MarketWatch) -- Merck & Co. MRK, -0.10% and Schering-Plough Corp. SGP, +5.21% said they will complete their $41 billion merger after the market's close on Tuesday. As a result, Schering-Plough's stock will cease trading later Tuesday. e mais »

Merck to buy Schering-Plough for $41.1 billion MarketWatch Before the opening bell Monday, the two major drugmakers said they have agreed to a merger that calls for Schering-Plough SGP, -2.68% shareholders to receive $10.50 in cash and 0.5767 in Merck MRK, -0.19% stock for each share of Schering-Plough.

CNNMoney.com

Merck and Schering-Plough in $41B merger CNNMoney.com ... and Swiss drugmaker Roche Holding AG continues to pursue a $40 billion hostile bid of Genentech Inc. (DNA). Shares of Merck (MRK, Fortune 500) fell about 11% and Schering-Plough (SGP, Fortune 500) shares were up about 11% in premarket trading. Merck to Buy Rival for $41 BillionWall Street Journal todos os 2.448 artigos de notícias »

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers ... Markets Insider LONDON, July 24, 2018 /PRNewswire/ --. Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs. The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder ...

Merck to Buy Schering-Plough in $41.1 Billion Cash and Stock Deal Seeking Alpha (blog) Not to be outdone by Pfizer (NYSE:PFE) / Wyeth (WYE), Merck (NYSE:MRK) and Schering-Plough (SGP) announced that their Boards of Directors have unanimously approved a merger. Schering has a strong pipeline and was my best of breed to be acquired ...

CNBC

How innovators and investors are working with patients and ... CNBC CNBC presents a one-day event at NYC's Roosevelt Hotel that brings together top health care investors, CEOs and technologists to explore the innovations that will drive better outcomes, financially and clinically. Every health care company seeks to ...

Reuters

Schering-Plough to buy Akzo's Organon for $14.4 bln Reuters Schering-Plough shares gained 0.5 percent in early U.S. trade as the firm said the acquisition, which is due to close by the end of 2007, would lift earnings per share by 10 U.S. cents in the first full year. Analysts said the acquisition would help ...

Franceinfo

Hérouville: le laboratoire pharmaceutique Schering-Plough bientôt ... Franceinfo Depuis 2015, le groupe Merck Sharp & Dohme, propriétaire du laboratoire Schering-Plough, souhaite vendre son site d'Hérouville-Saint-Clair. Un projet a été présenté ce vendredi aux salariés : le groupe français Cenexi est prêt à investir 7 millions d ... e mais »

EurekAlert (press release)

Three or more cups of coffee daily halves mortality risk in patients ... EurekAlert (press release) Amsterdam, The Netherlands, September 25, 2017 - Patients infected by both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at specific risk of end-stage liver disease and greater risk of cardiovascular diseases and cancer. In ... e mais »

Scientists find a way to cure hepatitis C with 6 weeks of treatment EurekAlert (press release) "Given the high cost of sofosbuvir and ledipasvir, and the associated side effects that occur during treatment, we set out to assess whether shortened treatment duration could be an effective option for acute Hepatitis C patients," said Katja Deterding ... e mais »

Medscape

Cut LDL-C for CV Risk-Reduction, but How Matters: Meta-Analysis Medscape ... P<0.001) and 25% lower risk with intensive diet, bile-acid sequestrants, ileal bypass surgery, or ezetimibe (Zetia, Merck/Schering Plough)?all therapies that help clear cholesterol by upregulating the LDL receptor (RR 0.75, 95% CI 0.66-0.86; P=0.002).

Ouest-France

Calvados. L'usine pharmaceutique veut multiplier sa production par 4 Ouest-France Il est presque loin le temps où MSD (Merck Sharp and Dohme), ancien propriétaire de l'usine pharmaceutique Schering-Plough, installée à Hérouville-Saint-Clair, près de Caen, annonçait la suppression de 83 postes en juin 2015. Pire : en 2011, déjà, la ...

Adverum Biotechnologies Appoints Linda Neuman, MD as Vice ... GlobeNewswire (press release) Earlier in her career, Dr. Neuman held roles of increasing responsibility at Covidien Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Schering-Plough. She began her ... On the date she commenced her employment, Adverum granted Dr. Neuman a stock ... e mais »

Ouest France Entreprises

Près de Caen, Schering-Plough aurait un repreneur Ouest France Entreprises Entreprise de la région. Le groupe pharmaceutique Cenexi reprendrait les 261 salariés et investirait 7 millions d'euros en trois ans. Le projet va être présenté dans quelques jours. Une première annonce a été faite aux salariés vendredi. Hier, c'est la ... e mais »

CNBC

One-on-One with Schering-Plough CEO Fred Hassan CNBC When Hassan took the helm of a struggling Schering-Plough in 2003, he bought back stock as a way to calm the nerves of those who thought the company was headed toward a downward spiral. To reassure analysts and shareholders, Hassan told Cramer ...

Ouest-France

Industrie pharmaceutique. Schering Plough devrait s'appeler Cenexi ... Ouest-France La prospection a démarré en septembre 2015. Nous avons consulté plus de 400 entreprises, indique Catherine Boulangé. Et huit sont venues visiter nos installations, dont le groupe Cenexi. » Une liste réduite a été étudiée en mars 2016 et c'est ...